TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02000973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: General anesthesia combined with thoracic epidural 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: General anesthesia combined with thoracic epidural 0.3% ropivacaine
Study: NCT03438955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor + Pritor
Description: Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritor + Omacor
Description: Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
Study: NCT01064102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg
Study: NCT02314065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention (Face-to-face)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention (Internet-based)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system.
Study: NCT02569372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)
Study: NCT02000973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: General anesthesia combined with thoracic epidural 0.9% normal saline
Study: NCT03365739

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator 1
Description: Mango (pulp/flesh) (500 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator 2
Description: Mango (500 g) + Vitamin C (100 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Comparator
Description: Vitamin C (100 mg)
Study: NCT03140644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with thoracic sarcoidosis
Description: Ultra-low dose CT scan and MRI with UTE
Study: NCT02569372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: GC1102(Recombinant Hepatitis B Human Immunoglobulin)
Study: NCT02396433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin will be given on days 1 and 8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7449
Description: E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
Study: NCT03848650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OpSens Medical OptoWire
Description: The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFR
Description: A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
Study: NCT05951062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavior management for anti-hypertensive medication
Description: five sessions of educational interview and home visiting to improve medication-related self-management skills

Intervention type: OTHER
Group type: OTHER
Intervention: placebo group
Description: treatment as usual
Study: NCT04142853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training intervention + Dance intervention
Description: Training intervention + Dance intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intervention + Dance intervention
Description: Training intervention + Dance intervention
Study: NCT02029625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1205
Description: rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin and ezetimibe
Description: coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
Study: NCT02450383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous subepithelial connective tissue graft
Description: Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Study: NCT03895086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Physical Activity
Description: An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Classic Physical Activity
Description: One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association
Study: NCT00952445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0903131 Besylate
Description: Once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0903131 Besylate
Description: Once daily, oral
Study: NCT04233151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1203
Description: 6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 regimen
Description: The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
Study: NCT02801292

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Single bolus of Ketamine .25 milligrams per kilogram of weight.
Study: NCT02329704

Intervention type: PROCEDURE
Intervention: HBA Testing
Description: The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm.

Intervention type: PROCEDURE
Intervention: HBA Testing
Description: The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm.

Intervention type: BIOLOGICAL
Intervention: Bacterial contamination
Description: Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.

Intervention type: BIOLOGICAL
Intervention: Bacterial contamination
Description: Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
Study: NCT03983668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: Immunostimulatory therapeutic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy
Study: NCT04668729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation
Description: Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position.
Study: NCT01961466

Intervention type: OTHER
Intervention: psychological and social self-administered questionnaires
Study: NCT01214031

Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal laser endomicroscopy (CLE)
Description: Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
Study: NCT04300244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 vaccine + leukine
Description: The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study: NCT02733328

Intervention type: PROCEDURE
Intervention: CPB Surgery

Intervention type: PROCEDURE
Intervention: CPB Surgery
Study: NCT00952445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study: NCT00938821

Intervention type: PROCEDURE
Intervention: Caudal block
Description: Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
Study: NCT03038607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: This group were subjected to aspirin 75 mg once daily for 6 weeks.
Study: NCT04271371

Intervention type: OTHER
Intervention: Not yet developed
Description: A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
Study: NCT01460875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
Study: NCT04323137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical records-based recommendation
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical records-based recommendation
Description: Mailed letter, SMS, and/or patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm-based recommendation
Description: Mailed letter, SMS, and/or patient portal message
Study: NCT01587261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Study: NCT02180256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratching
Description: The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratching
Description: The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
Study: NCT02150057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breg Fusion Unloading Brace
Description: This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
Study: NCT02090049

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Puravita Breakfast
Description: The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
Study: NCT00470093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon-α

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-6
Study: NCT00664560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg naproxen/20 mg esomeprazole bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex
Description: 200 mg celecoxib qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill bid
Study: NCT04300244

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
Study: NCT01812759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Nasal Spray
Description: 100 mcg nasal spray administered in each nostril.
Study: NCT02759679

Intervention type: OTHER
Group type: OTHER
Intervention: Human breath samples

Intervention type: OTHER
Group type: OTHER
Intervention: Human breath samples
Study: NCT01934660

Intervention type: DRUG
Intervention: Fludeoxyglucose F18

Intervention type: DRUG
Intervention: Fludeoxyglucose F18

Intervention type: DRUG
Intervention: Fludeoxyglucose F18
Study: NCT00664560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Antacid
Description: Antacid Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study: NCT03454399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction orogastric tube which is attached to TEE probe
Description: Suction orogastric tube which is attached to TEE probe
Study: NCT01344681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin sodium
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever.
Study: NCT02174367

Intervention type: DEVICE
Intervention: Transient elastography
Description: a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
Study: NCT03015649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVI SCOUT Surgical Guidance System
Description: SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
Study: NCT02041975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutriose FB06
Description: Wheat dextrin soluble fibre

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04347213

Intervention type: BEHAVIORAL
Intervention: Regular lifestyle in different circumstances
Description: Participants' lifestyle will be followed over the years.
Study: NCT01812759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone PCA
Description: Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone PCA
Description: Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
Study: NCT00927784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor cells (RevascorTM)
Description: Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cryoprotective media alone
Description: Participants will receive intramyocardial injections of cryoprotective media (placebo).
Study: NCT03498690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrative
Description: Stakeholder groups: a-b

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Role specific
Description: Stakeholder groups: a or b
Study: NCT01812759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 1 placebo nasal spray administered in each nostril.